

FIGURE 1

1/25

TTGGCGGGCGGAAGCGGCCACAACCGGGCATCGAAAAGATTCTTAGAACGCCGTACCA
GCCCGCTCTCTCAGGACAGCAGGCCCTGCTCTGTCGGGCGCCGCTCAGCGTGC
TCCGCCCTCAGGTTCTTTCTAATTCAAATAAACTTGCAAGAGGACTATGAAAGATT
ATGATGAACCTCTCAAATATTATGAATTACATGAAACTATTGGGACAGGTGGCTTGCAA
AGGTCAAACCTGCCATATCCTACTGGAGAGATGGTAGCTATAAAATCATGGATA
AAAACACACTAGGGAGTGAATTGCCCGGATCAAACGGAGATTGAGGCCTGAAGAAC
TGAGACATCAGCATATATGTCAACTCTACCATGTGCTAGAGACAGCCAACAAAATATTCA
TGGTTCTGAGTACTGCCCTGGAGGAGAGCTGTTGACTATATAATTCCAGGATGCC
TGTCAGAAGAGGAGACCCGGGTTGCTTCCGTAGATAGTATCTGCTGTTATGTGC
ACAGCCAGGGCTATGTCACAGGGACCTAAGCCAGAAAATTGCTGTTGATGAATATC
ATAAATTAAAGCTGATTGACTTGGTCTCTGTGAAAACCAAGGTAACAAGGATTAC
ATCTACAGACATGCTGTGGGAGTCTGGCTTATGCAGCACCTGAGTTAACAGGCAAAT
CATATCTGGATCAGAGGCAGATGTTGGAGCATGGCATACTGTTATGTTCTATGT
GTGGATTCTACCATTGATGATGATAATGTAATGGCTTATACAAGAAGGATTATGAGAG
GAAAATATGATGTTCCAAGTGGCTCTCTCCAGTAGCATTCTGCTTCTCAACAAATGC
TGCAGGGGACCCAAAGAAACGGATTCTATGAAAATCTATTGAACCATCCCTGGATCA
TGCAAGATTACAACATCCTGTTGAGTGGCAAAGCAAGAACATCCTTTATCACCTCGATG
ATGATTGCGTAACAGAACCTTCTGTACATCACAGAAACACAGGCAAACAAATGGAGGATT
TAATTTCAGTGGCAGTATGATCACCTCACGGCTACCTATCTCTGCTTCTAGCCAAGA
AGGCTCGGGAAAACCAGTCGTTAAGGCTTCTCTCTGTGGACAAGCCAGTG
CTACCCCATTCACAGACATCAAGTCAAATAATTGGAGTCTGGAAGATGTGACCGCAAGTG
ATAAAAATTATGTGGGGATAATAGACTATGATTGGTGTGAAGATGATTATCACAG
GTGCTGCTACTCCCCGAACATCACAGTTACCAAGTACTGGACAGAACATCAAATGGGTGG
AATCTAAATCATTAACTCCAGCCTTATGCAGAACACCTGCAAATAAAATTAAAGAACAAAG
AAAATGTATATACTCCTAAGTCTGTTAAAGAATGAAGAGTACTTTATGTTCTGAGC
CAAAGACTCCAGTTAATAAGAACCAACAGCATAAGAGAGAAACTCACTACGCCAAATCGTT
ACACTACACCCCTCAAAGCTAGAAACCAAGTGCCTGAAAGAACCTCAAATTAAACCA
TAAATTCAACAGGAACAGACAAGTTAATGACAGGTGTCATTAGCCCTGAGAGGCGGTGCC
GCTCAGTGAATTGGATCTCAACCAAGCACATATGGAGGAGACTCCAAAAGAAAGGGAG
CCAAAGTGTGAGGCTTGAAAGGGGTTGGATAAGGTTATCACTGTGCTCACCAGGA
GCAAAGGAAGGGTCTGCCAGAGACGGGCCAGAACAGACTAAAGCTTCACTATAATGTGA
CTACAACAGTAACTGCAACTGTTGAAATAATGTCTATTCTCCAA
AGAAGCATGTTGACTTGTACAAAGGGTTATACACTGAAGTGTCAAACACAGTCAGATT
TTGGGAAAGTGACAATGCAATTGAATTAGAAGTGTGCCAGCTCAAAACCGATGTGG
TGGGTATCAGGAGGCAGCGGCTTAAGGGCGATGCCCTGGTTACAAAGATTAGTGGAAAG
ACATCCTATCTAGCTGCAAGGTATAATTGATGGATTCTCCATCCTGCCGATGAGTGTG
GGTGTGATACAGCCTACATAAAAGACTGTTATGATGCCCTGATTAAAGTTCACTGGAA
CTACCAACTGTTCTAAAGAGCTATCTTAAGACCAATATCTTGTGTTAAACAA
GATATTATTTGTGATGAATCTAAATCAAGCCCACCTGTCATTATGTTACTGTCTTTT
TAATCATGTTGTTGATTAATAATTGTTGACTTCTTAGATTCACTCCATATGTG
AATGTAAGCTCTTAACATATGTCCTTGTAATGTGTAATTCTTCTGAAATAAAACCAT
TTGTGAATAT

FIGURE 2

2/25

MKDYDELLKYYELHETIGGGFAKVKLACHILTGEMVAIKIMDKNTLGSIDLPIKTEIEA
LKNLRHQHICQLYHVLETANKIFMVLEYCPGGELFDYIISQDRLSEEETRVVFRQIVSAV
AYVHSQGYAHRDLKPENLLFDEYHKLKLIDFGLCAPKGKDYHLQTCCGSLAYAAPELI
QGKSYLGSEADVWSMGILLYVLMCGFLPFDDDNVMALYKKIMRGKYDVPKWLSPSSILL
QQMLQVDPKKRISMKNLLNHPIQMODYNPVEWQSKNPFIHLLDDCVTELSVHHRNNRQT
MEDLISLWQYDHLTATYLLLAKKARGKPVRRLSSFSCGQASATPFTDIKSNNWSLEDV
TASDKNYVAGLIDYDWCEDDLSTGAATPRTSQFTKYWTEESNGVESKSLTPALCRTPANKL
KNKENVYTPKSAVKNEEYFMFPEPKTPVNKNQHKREILTPNRYTTPSKARNQCLKETPI
KIPVNSTGTDKLMGVISPERCRSVELDLNQAHMEETPKRKGAKVFGSLERGLDKVITV
LTRSKRKGSARDGPRLKLHYNVTTTRLVNPDQLLNEIMSILPKKHDFVQKGYTLKCQT
QSDFGKVTMQFELEVSQLQKPDVVGIRRQLKGDAWVYKRLVEDILSSCKV

N-glycosylation site.

354-357
485-488
562-565

cAMP- and cGMP-dependent protein kinase phosphorylation site.

250-253
546-549

Tyrosine kinase phosphorylation site.

2-10
421-427
630-638

N-myristoylation site.

340-345

Microbodies C-terminal targeting signal.

649-652

Leucine zipper pattern.

165-186

Serine/Threonine protein kinases active-site signature.

128-140

Protein kinase domain
11-263

Kinase associated domain 1
602-651

FIGURE 3

3/25

GTGCGATCCGGGCCGAGGGCATCAGACGGCGGCTGATTAGCTCCGGTTGCATCACCC
GGACCGGGGATTAGCTCCGGTTGCATCACCCGGACCGGGGCCGGCGCAGGAGAC
TCGCAGCGGAAGTGGAGGCGGCTCCGCGCGTCCGCTGCTAGGACCGGGCAGGGCTGG
AGCTGGCTGGATCCCGAGCTCGGCAGCGCAGCGGGCCGGCCACCTGCTGGTGC
CTGGAGGCTCTGAGCCCCGGCGGCCGGCCACCGGAAACGACGGGCGAG**ATGCGA**
GCCACCCCTAGCTGCTCTGGGGTCCCTGTCCAGGAAGAAGCGGTTGGAGTTGGAT
GACAACCTAGATACCGAGCGTCCCGTCCAGAAACGAGCTGAAGTGGGCCCCAGCCCAGA
CTGCCCCCTGCCTGTTGCCCCCTGAGCCACCTACTGCTCCAGATCGTGAACGTGCTG
GCCACTGCCCTCCGCTTGGGCCATGTCTCTGGAGCCCAGGAGGGCGGGCGGGCC
TACCAAGGCCCTGCACTGCCCTACAGGCACTGAGTATACCTGCAAGGTGTACCCGTCCAG
GAAGCCCCGGCGTGGAGCCCTATGCGCGCTGCCCGACAAGCATGTGGCTCGG
CCCACTGAGGTCTGGCTGGTACCCAGCTCCTACGCCTTTTCACTGGACCCATGGG
GACATGCACAGCTGGTGCAGAGCCACCGTATCCCTGAGCCTGAGGCTGCCGTGCTC
TTCCGCCAGATGGCACCGCCCTGGCGCACTGTCACCAGCACGGTCTGGCTCGTGAT
CTCAAGCTGTGCTGCTTGTCTCGCTGACCGTGAGAGGAAGAAGCTGGTGTGGAGAAC
CTGGAGGACTCCTGCGTGTGACTGGGCCAGATGATTCCCTGTTGAGAACACGCGTGC
CCAGCCTACGTGGGACCTGAGATACTCAGCTCACGGCCTCATACTGGCAAGGCAGCC
GATGTCGGAGCCTGGCGCTTCACCAGTCGGCCGCACTACCCCTCCAG
GACTCGGAGCCTGTCCTGCTCTCGGCAAGATCCGCCGCGGGGCTACGCCCTGCCTGCA
GGCCTCTGCCCTGCCGCTGTCTGGTCGCTGCCCTTCGTCGGAGCCAGCTGAA
CGGCTCACGCCACAGGCATCCTCTGCACCCCTGGCTGCGACAGGACCCGATGCCCTTA
GCCCAACCGATCCCCTCTGGAGGCTGCCAGGTGGTCCCTGATGGCTGGGCTG
GACGAAGCCAGGGAGAGGGAGACAGAGAAGTGGTCTGTATGGC**TAGGACCACCC**
ACTACACGCTCAGCTGCCAACAGTGGATTGAGTTGGGGTAGCTCCAAGCCTCTCCTG
CCTCTGAACTGAGCCAAACCTTCAGTGCCTTCCAGAAGGGAGAAAGGCAGAACGCTGTG
GGAGTGTGCTGTGACACATCTGCTTGTCCACACACATGCACTTCTGCTGGGTGCT
TATCAGGTGCAAGCCCTGTTCTGGTGTGGAGTACAGCAGTGAGCAAAGGAGACAAT
ATTCCCTGCTCACAGAGATGACAACACTGCCATCCTTGAGCTGACAACACTTTCCATGAC
CATAGGTCACTGCTCAACTGGTACACTGGTACCTTGAGCTGTCGGCCTCCACTGATGCTGG
TGCTCAGGACACCTCTGCTCCAAGGACAATCCCTTCAAAACAAACAGCTGCCCTTGAT
CTTGTACCTTTCAGAGAAAGGGAGGTATCCCTGTCCTGCCAAAGGCTCCAGGCCCTCC
GCAACTCAGGACCCAAGGCCAGCTCACTCTGGGAACTGTGTTCCAGCATTCTGTCCTC
TTGATTAAGAGATTCTCCTCCAGGCCTAACGCTGGGATTGGCCAGAGATAAGAATCC
AAACTATGAGGCTAGTTCTGCTAACTCAAGACTGTTCTGGAATGAGGGTCCAGGCC
TCAACCATGGGCTTCTGACCTGAGCACCAAGGTTGAGGGACAGGATTAGGCAGGGTCTG
TCCTGTGCCACCTGAAAGTCCCAGGTGGGACTCTCTGGGACACTTGGGTCCACAA
TCCCAGGTCCATACTCTAGGTTGGATACCATGAGTATGTATGTTACCTGTGCCATAAT
AAAGGAGAATTATGAAATAAAAAAAAAAAAAAA

FIGURE 4

4/25

MRATPLAAPAGSLSRKKRLELDDNLDTERPVQKRARSGPQPRLPPCLLPLSPPTAPDRAT
AVATASRLGPYVLLPEEGGRAYQALHCPTGTEYTCVYPVQEAPAVLEPYARLPPHKHV
ARPTEVLAGTQLLYAFFTRTHGDMHSLVRSRHRIPPEPEAAVLFRQMATALAHCHQHGLVL
RDLKLCRFVFAADRERKKLVLENLEDSCVLTGPDDSLWDKHACPAYVGPEILSSRASYSGK
AADVWSLGVALFTMLAGHYPFQDSEPVLLFGKIRRGAYALPAGLSAPARCLVRCLLREP
AERLTATGILLHPWLRQDPMP LAPTRSHLWEAAQVVPDGLGLDEAREEEGDREVVLYG

N-myristoylation site.

91-96
341-346

Protein kinase domain

71-315

FIGURE 5

5/25

GAAGTTCTCACTAGGGTCTTCTGGCCAGCCTTGACTGAAGCTGGCTGGAGACAG
GGCATTAGAGAAGTGACTCATAGATGGCTAAAGAACGGGCCACTCAAGGACCAGG
ACAGAGGGAAAGAGGCCAACCCAGCTGGACCACAGCAAACCCATTGCCTTGAGAGAA
AGAAGAGGACCCGGTGAACATGCTGCTGAAGAAACACACGGAGGACATCAGCAGCG
TCTACGAGATCCCGAGAGGCTCGGCTGGGTGCCTCTCCGAGGTGGTCTGGCCAGG
AGCGGGCTCCGCACACCTCGTGGCCCTAAGTCATCCCCAAGAACGGCCCTCCGGGCA
AGGAGGCCCTGGTGGAGAACGAGATCGCAGTGCTCCGTAGGATCAGTCACCCAAACATCG
TCGCTCTGGAGGATGTCCACGAGAGCCCTCCACCTCTACCTGGCCATGGAACATGGTGA
CGGGTGGCGAGCTGTTGACCGCATATGGAGCGCGCTCCTACACAGAGAAGGATGCCA
GCCATCTGGTGGGTCAAGGTCTGGCGCGTCTCTACCTGCACAGCCTGGGATCGTGC
ACCGGGACCTCAAGCCGAAAACCTCTGTATGCCACGCCCTTGAGGACTCGAACATCA
TGGTCTCTGACTTTGACTCTCCAAATCCAGGCTGGAACATGCTAGGCACGCCCTGTG
GGACCCCTGGATATGTGGCCCCAGAGCTTGGAGCAGAAACCTACGGGAAGGCCGTAG
ATGTGTGGCCCTGGCGTCATCTCCTACATCCTGCTGTGGTACCCCCCTCTACG
ACGAGAGCGACCTGAGCTCTCAGCCAGATCCTGAGGGCCAGCTATGAGTTGACTXTC
CTTCTGGATGACATCTCAGAACAGGAAAGACTTATTCCGCACCTCTGGAGCGAG
ACCTTCAGAACAGAGGTTCACCTGCCAACAGGCCCTGCGGACCTTGGATTTGGACA
CAGGCTTGGCAGGGACATCTAGGGTTGTCAGTGAGCAGATCCGGAAAGAACTTGCTT
GGACACACTGGAAGCGAGCCTCAATGCCACCTTGTCTGCCACATCCGGAAAGCTGG
GGCAGATCCCAGAGGGCGAGGGGGCTCTGAGCAGGGCATGGSCCGXACAGCCACTXAG
GCCTCGTGTGGCAGCCCCAAGTGGTATGCCAGGXAGATGCCAGGCCAAGTGG
AXTGAXCCCCAGATTXCTTXC

FIGURE 6

6/25

MLLLKKHTEDISSVYEIRERLGSGAFSEVVLAQERGSAHLVALKCIPKKALRGKEALVEN
EIAVLRISHPNIVALEDVHESPSHLYLAMELVTGELFDRIMERGSYTEKDASHLVGQV
LGAVSYLHSLGIVHRLDKPENLLYATPFEDSKIMVSDFGLSKIQAGNMLGTACGTPGYVA
PELLEQKPYGKAVDVWALGVISYILLCGYPPFYDESDPELFSQILRASYEFDXPFWDDIS
ESGKDFIRHLLERDLQKRFTCQQALRDLWIFWDTGFGRDILGFVSEQIRKNFAWTHWKRA
FNATLFLRHIRKLQIPEGEQGMXRHSXGLRAGQPPKW

N-glycosylation site.

302-305

cAMP- and cGMP-dependent protein kinase phosphorylation site.

5-8
66-69
257-260

Tyrosine kinase phosphorylation site.

101-108

N-myristoylation site.

118-123
166-171
170-175
334-339

Serine/Threonine protein kinases active-site signature.

132-144

Protein kinase domain

15-270

FIGURE 7

7/25

TASK110 expression data

Tumor samples versus cell lines




FIGURE 8

8/25

TASK119 expression: tumor samples versus cell lines




FIGURE 9A

9/25

Lung cancer in situ




FIGURE 9B

10/25

Lung cancer in situ




FIGURE 10A

11/25

Kidney cancer in situ




FIGURE 10B

12/25

Kidney cancer in situ




FIGURE 11A

13/25




FIGURE 11B

14/25

Proliferation




FIGURE 11C

15/25




FIGURE 11D

16/25




FIGURE 11E

17/25




FIGURE 11F

18/25




FIGURE 11G

19/25




FIGURE 11H

20/25




FIGURE 11 (I)

21/25

BT549




FIGURE 12

22/25

786-O cells





FIGURE 13
23/25



→ 4 control genes




FIGURE 15

25/25

